Serial Monitoring of Plasma ctDNA in Metastatic Colorectal Cancer Patients Detects Changes in Key Mutations and Disease Progression Using the Follow It Assay from the Exactis Trial Free Infographic

Request Your Free Infographic Now:

"Serial Monitoring of Plasma ctDNA in Metastatic Colorectal Cancer Patients Detects Changes in Key Mutations and Disease Progression Using the Follow It Assay from the Exactis Trial"

Free Infographic: "Serial Monitoring of Plasma ctDNA in Metastatic Colorectal Cancer Patients Detects Changes in Key Mutations and Disease Progression Using the Follow It Assay from the Exactis Trial"

Colorectal cancer is the third leading cause of cancer-related deaths. Clinical responses of metastatic colorectal cancer to first-line treatment range from 35 to 60 percent, but even responders inevitably develop therapeutic resistance. Liquid biopsies have become a useful tool in precision medicine for therapy selection and have immense potential as a monitoring tool for the emergence of therapy resistance.
View full description >

Get Started

Complete the form below:

Work Email Address

First Name

Last Name

Company Name

Job Title

Job Area

Please Specify
for Other:

Work Phone Number

Company Size

Company Industry

Please Specify
for Other:

Company Street Address

Company Suite/Office

Company Postal/Zip Code

Company City

Company State

Company Country

Summary

By downloading this material, you consent for GenomeWeb to share your contact information with the sponsor, who may occasionally send you relevant information on their products and services. You may unsubscribe or change your email preferences through links in emails you receive. For more information, see the GenomeWeb Privacy Policy.

Valid email address is required to fulfill your request.

Complete and verifiable information is required in order to receive this content.

Request Your Free Infographic Now: